Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 21Terminated 4Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

Nivolumab 25pembrolizumab 20Ipilimumab 15toripalimab 12Temozolomide 11Biopsy 8Dacarbazine 7Cyclophosphamide 6Blood Specimen Collection 6trametinib 5fludarabine 5dabrafenib 5camrelizumab 5atezolizumab 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5durvalumab 4binimetinib 4aldesleukin 4Interleukin-2 4Injections 4Carboplatin 4tislelizumab 3palbociclib 3encorafenib 3apatinib 3Sorafenib 3Paclitaxel 3Introns 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Melanoma × MART-1 Antigen × Clear all
NCT00010309 2014-01-06

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Dermatologic

Melanoma

NCT00037037 2013-12-18

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1 Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡